WO2001030383A3 - Arzneimittel für die toleranzinduktion - Google Patents

Arzneimittel für die toleranzinduktion Download PDF

Info

Publication number
WO2001030383A3
WO2001030383A3 PCT/EP2000/010594 EP0010594W WO0130383A3 WO 2001030383 A3 WO2001030383 A3 WO 2001030383A3 EP 0010594 W EP0010594 W EP 0010594W WO 0130383 A3 WO0130383 A3 WO 0130383A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
order
induce tolerance
antigen
induce
Prior art date
Application number
PCT/EP2000/010594
Other languages
English (en)
French (fr)
Other versions
WO2001030383A2 (de
Inventor
Thomas Wilckens
Original Assignee
Bionetworks Gmbh
Thomas Wilckens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionetworks Gmbh, Thomas Wilckens filed Critical Bionetworks Gmbh
Priority to AU19972/01A priority Critical patent/AU784245B2/en
Priority to EP00983094A priority patent/EP1223974A2/de
Priority to JP2001532800A priority patent/JP2003512438A/ja
Priority to KR1020027005465A priority patent/KR20020057986A/ko
Priority to CA002388974A priority patent/CA2388974A1/en
Priority to NZ518567A priority patent/NZ518567A/en
Publication of WO2001030383A2 publication Critical patent/WO2001030383A2/de
Publication of WO2001030383A3 publication Critical patent/WO2001030383A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Die Erfindung betrifft ein Arzneimittel, umfassend Inhibitoren der 11-β-Hydroxysteroid-Dehydrogenase in Kombination mit einem Antigen zur Verbesserung und Optimierung der Toleranzinduktion.
PCT/EP2000/010594 1999-10-28 2000-10-27 Arzneimittel für die toleranzinduktion WO2001030383A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU19972/01A AU784245B2 (en) 1999-10-28 2000-10-27 Medicament in order to induce tolerance
EP00983094A EP1223974A2 (de) 1999-10-28 2000-10-27 Arzneimittel für die toleranzinduktion
JP2001532800A JP2003512438A (ja) 1999-10-28 2000-10-27 免疫寛容を誘導するための薬剤
KR1020027005465A KR20020057986A (ko) 1999-10-28 2000-10-27 내성을 유도하기 위한 약물
CA002388974A CA2388974A1 (en) 1999-10-28 2000-10-27 Medicament in order to induce tolerance
NZ518567A NZ518567A (en) 1999-10-28 2000-10-27 Medicament comprising an inhibitor of 11-beta-hydroxysteroid dehydrogenase in combination with an antigen to induce and/or optimise tolerance induction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19951970A DE19951970A1 (de) 1999-10-28 1999-10-28 Arzneimittel für die Toleranzinduktion
DE19951970.6 1999-10-28

Publications (2)

Publication Number Publication Date
WO2001030383A2 WO2001030383A2 (de) 2001-05-03
WO2001030383A3 true WO2001030383A3 (de) 2001-11-08

Family

ID=7927188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/010594 WO2001030383A2 (de) 1999-10-28 2000-10-27 Arzneimittel für die toleranzinduktion

Country Status (9)

Country Link
EP (1) EP1223974A2 (de)
JP (1) JP2003512438A (de)
KR (1) KR20020057986A (de)
CN (1) CN1391479A (de)
AU (1) AU784245B2 (de)
CA (1) CA2388974A1 (de)
DE (1) DE19951970A1 (de)
NZ (1) NZ518567A (de)
WO (1) WO2001030383A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
US20030198965A1 (en) 2002-04-19 2003-10-23 Isis Pharmaceuticals Inc. Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
CA2516291C (en) * 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20100087413A1 (en) * 2003-09-22 2010-04-08 Thomas Wilckens Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
WO2006059507A1 (ja) * 2004-11-30 2006-06-08 Sankyo Company, Limited 11β-HSD1アンチセンス化合物
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
CN107261154A (zh) 2011-04-29 2017-10-20 西莱克塔生物科技公司 致耐受性合成纳米载体
AU2014262163A1 (en) 2013-05-03 2015-11-19 Selecta Biosciences, Inc. Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance
EP3189138A4 (de) 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Verfahren und zusammensetzungen zur abschwächung der immunantworten auf antivirale geneditierende transfervektoren
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
JP2019182845A (ja) * 2018-04-02 2019-10-24 学校法人藤田学園 キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
WO1990004399A1 (en) * 1988-10-24 1990-05-03 The University Court Of The University Of Edinburgh Administration of corticosteroids
WO1991004030A1 (en) * 1989-09-25 1991-04-04 University Of Utah Use of steroid hormones in compositions for inducing t cell lymphokine production
JPH04243833A (ja) * 1991-01-28 1992-08-31 Tsumura & Co １１β−ヒドロキシステロイドデヒドロゲナーゼ阻害剤
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5591771A (en) * 1991-12-17 1997-01-07 Michel Fockerman Use of propolis components as an adjuvant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883240A (en) * 1995-08-24 1999-03-16 Baker Medical Research Institute Genetic sequences encoding glucocorticoid dehydrogenases and uses therefor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
WO1990004399A1 (en) * 1988-10-24 1990-05-03 The University Court Of The University Of Edinburgh Administration of corticosteroids
WO1991004030A1 (en) * 1989-09-25 1991-04-04 University Of Utah Use of steroid hormones in compositions for inducing t cell lymphokine production
JPH04243833A (ja) * 1991-01-28 1992-08-31 Tsumura & Co １１β−ヒドロキシステロイドデヒドロゲナーゼ阻害剤
US5591771A (en) * 1991-12-17 1997-01-07 Michel Fockerman Use of propolis components as an adjuvant
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AUTERI A ET AL: "Effect of a long-term treatment with two different corticosteroids on patients suffering from rheumatoid arthritis: Clinical and immunological study.", INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, vol. 10, no. 2, 1994, pages 67 - 75, XP001002029, ISSN: 0255-9625 *
DATABASE WPI Section Ch Week 199241, Derwent World Patents Index; Class B04, AN 1992-337593, XP002167668 *
DI ZHANG YIN ET AL: "Inhibition of 11-beta-hydroxysteroid dehydrogenase obtained from guinea pig kidney by furosemide, naringenin and some other compounds.", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 49, no. 1, 1994, pages 81 - 85, XP001002027, ISSN: 0960-0760 *
HULT MALIN ET AL: "Selective inhibition of human type 1 11beta-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics.", FEBS LETTERS, vol. 441, no. 1, 11 December 1998 (1998-12-11), pages 25 - 28, XP002167666, ISSN: 0014-5793 *
KROES B H ET AL: "Inhibition of human complement by beta-glycyrrhetinic acid.", IMMUNOLOGY, vol. 90, no. 1, 1997, pages 115 - 120, XP002167665, ISSN: 0019-2805 *
RAO CHAVALI S ET AL: "AN IN VITRO STUDY OF IMMUNOMODULATORY EFFECTS OF SOME SAPONINS", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY,US,ELMSFORD,NY, vol. 9, no. 6, 1987, pages 675 - 683, XP000863703, ISSN: 0192-0561 *

Also Published As

Publication number Publication date
KR20020057986A (ko) 2002-07-12
NZ518567A (en) 2004-09-24
WO2001030383A2 (de) 2001-05-03
JP2003512438A (ja) 2003-04-02
AU784245B2 (en) 2006-02-23
EP1223974A2 (de) 2002-07-24
CA2388974A1 (en) 2001-05-03
DE19951970A1 (de) 2001-05-03
CN1391479A (zh) 2003-01-15
AU1997201A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
AU2002364148A1 (en) Delivering content and advertisement
AU2001239945A1 (en) Systems and methods enabling anonymous credit transactions
AU2003271926A1 (en) Facilitating and authenticating transactions
WO2001046830A8 (en) Business transactions using the internet
AU2001264639A1 (en) Package delivery systems and methods
AU2001272879A1 (en) Secure and reliable document delivery
AU2002215230A1 (en) Internet commerce system and the method
AU2001251155A1 (en) Facilitating transactions between merchant, associate, and user
AU4020501A (en) Enhancing touch and feel on the internet
AU2001238648A1 (en) Generalized text localization in images
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
AU2002238153A1 (en) Multimedia and computing system
HK1037424A1 (en) Laminated piezoelectric body and method fo producing the same.
AU2002243246A1 (en) Cddo-compounds and combination therapies thereof
WO2001030383A3 (de) Arzneimittel für die toleranzinduktion
AU4820100A (en) Mosfet with field reducing trenches in body region
AU2001215798A1 (en) Click-to-add, jot-it-down, and add banner
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
AU2001231210A1 (en) System and method for electronically facilitating impulse transactions
AU2001282046A1 (en) Verification of thickness modulations in or on sheet-type products
AU2001236716A1 (en) Antigenic complexes and methods
AU2002243386A1 (en) Rf2a and rf2b transcription factors
AU2001261750A1 (en) Laminate and its use
AU7458201A (en) Laminate and use thereof
AU2001258911A1 (en) Internet advertisement system and method in connection with voice humor services

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000983094

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 19972/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 518567

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2388974

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027005465

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10110781

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 532800

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 008159920

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027005465

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000983094

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 518567

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 518567

Country of ref document: NZ